| __timestamp | Merck & Co., Inc. | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 11606000000 | 504755000 |
| Thursday, January 1, 2015 | 10313000000 | 838526000 |
| Friday, January 1, 2016 | 9762000000 | 1177697000 |
| Sunday, January 1, 2017 | 9830000000 | 1320433000 |
| Monday, January 1, 2018 | 10102000000 | 1556200000 |
| Tuesday, January 1, 2019 | 10615000000 | 1834800000 |
| Wednesday, January 1, 2020 | 8955000000 | 1346000000 |
| Friday, January 1, 2021 | 9634000000 | 1824900000 |
| Saturday, January 1, 2022 | 10042000000 | 2115900000 |
| Sunday, January 1, 2023 | 10504000000 | 2631300000 |
| Monday, January 1, 2024 | 2954400000 |
Data in motion
In the competitive landscape of the pharmaceutical industry, understanding the financial strategies of leading companies is crucial. Over the past decade, Merck & Co., Inc. and Regeneron Pharmaceuticals, Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Merck's SG&A expenses have fluctuated, peaking in 2014 and 2019, with a notable dip in 2020. In contrast, Regeneron has demonstrated a consistent upward trajectory, with expenses increasing by over 400% from 2014 to 2023. This divergence highlights Merck's strategic cost management and Regeneron's aggressive growth and expansion efforts. As the pharmaceutical sector continues to evolve, these trends offer valuable insights into the operational priorities and market positioning of these industry giants.
Merck & Co., Inc. vs Regeneron Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
R&D Insights: How Merck & Co., Inc. and Regeneron Pharmaceuticals, Inc. Allocate Funds
Who Optimizes SG&A Costs Better? Merck & Co., Inc. or Bristol-Myers Squibb Company
SG&A Efficiency Analysis: Comparing Novartis AG and Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. or Alnylam Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Regeneron Pharmaceuticals, Inc. or Viatris Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and Exelixis, Inc.
Regeneron Pharmaceuticals, Inc. vs Lantheus Holdings, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Apellis Pharmaceuticals, Inc.
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs MorphoSys AG Trends and Insights
Regeneron Pharmaceuticals, Inc. and Galapagos NV: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Novavax, Inc.